Kerlon (Betaxolol Hydrochloride)

• Betaxolol hydrochloride, a selective β1‑adrenergic antagonist, is used in cardiovascular conditions that require blood‑pressure reduction, decreased cardiac workload, and relief of ischemic chest pain.
• Hypertension: reduces both systolic and diastolic blood pressure by decreasing cardiac output and peripheral vascular resistance, providing long‑term control of elevated arterial pressure.
• Angina pectoris: lessens myocardial oxygen demand through heart‑rate slowing and contractility reduction, thereby alleviating chest pain episodes associated with physical activity or stress.
• Chronic stable angina: improves exercise tolerance by preventing ischemic episodes during sustained activity.

• Betaxolol hydrochloride selectively blocks β1‑adrenergic receptors located primarily in cardiac tissue. By inhibiting catecholamine binding, it reduces cyclic AMP formation, leading to decreased intracellular calcium influx. The result is a slower heart rate, reduced myocardial contractility, and lowered renin release, which together diminish cardiac output and systemic vascular resistance, thereby lowering arterial blood pressure and myocardial oxygen consumption.

Betaxolol may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Fatigue: feeling of tiredness or reduced energy.
• Dizziness: light‑headed sensation, especially when standing quickly.
• Cold extremities: reduced blood flow causing hands or feet to feel cold.
• Headache: mild to moderate head pain.
• Nausea: mild stomach upset or queasiness.
• Blurred vision: temporary visual disturbance.

Serious or Rare Side Effects

• Severe bradycardia: markedly slow heart rate that may require medical attention.
• Heart block: impairment of electrical conduction leading to arrhythmia.
• Bronchospasm: narrowing of airways, particularly in patients with asthma or COPD.
• Allergic reaction: rash, itching, or swelling that may progress to anaphylaxis.

When prescribing Betaxolol, clinicians should observe several precautionary measures to ensure patient safety.

• Blood pressure monitoring: regularly check systolic and diastolic values to assess therapeutic response.
• Heart rate assessment: monitor for bradycardia, especially in patients with pre‑existing conduction disorders.
• Asthma caution: use with care in patients with reactive airway disease due to possible bronchospasm.
• Gradual discontinuation: avoid abrupt cessation to prevent rebound hypertension.
• Renal impairment adjustment: consider dose reduction in patients with significant kidney dysfunction.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Betaxolol can interact with other medications, altering its efficacy or increasing the risk of adverse effects.

Major Interactions (Avoid)

• Non‑selective beta blockers: combined use may cause excessive bradycardia and hypotension.
• Calcium channel blockers (verapamil, diltiazem): additive negative inotropic effect leading to severe heart rate reduction.
• Anti‑arrhythmic agents (e.g., amiodarone): increased risk of conduction disturbances and heart block.

Moderate Interactions (Monitor Closely)

• NSAIDs: may diminish antihypertensive effect of Betaxolol.
• Insulin or oral hypoglycemics: beta‑blockade can mask hypoglycemia symptoms.
• Clonidine: abrupt withdrawal after combined therapy can precipitate rebound hypertension.